Menu Back to DIA-Advancing-Complex-Innovative-Clinical-Trial-Designs-to-Efficiently-Deliver-Medicines-to-Patients

Overview

NEW CONFERENCE

Complex Innovative Trial Designs (CID) have the potential to increase the efficiency and lower the cost of drug development which will accelerate patient access to life-altering therapies. The 21st Century Cures Act (Cures Act) and the sixth iteration of the Prescription Drug User Fee Act (PDUFA VI) recognize the need for CID and include provisions to advance their use to enhance medical product development. One such provision within PDUFA VI is the launch and implementation of the FDA CID Pilot Meeting Program which aims to foster discussions and education of the use and value of CID within drug development programs.

In an effort to promote CID, the unique DIA Advancing Complex Innovative Clinical Trial Designs to Efficiently Deliver Medicines to Patients conference will provide a platform for extensive scientific exchange among the FDA, other global health authorities including EMA, PMDA, and CFDA, patient advocates, and drug development innovators on CID topics such as master protocols, complex adaptive design, and Bayesian techniques, highlighting also the potential of alternative data sources.

Each session will begin with an introductory presentation by an FDA representative to set the stage followed by presentations and perspectives from a diverse group of expert speakers and panelists. The suitability of each CID topic and the proposed innovations from a US and global regulatory perspective, their usefulness from a patient perspective, and how challenges in the designs can be overcome, will be explored.

This conference is designed for key drug development decision makers including clinicians, regulatory scientists and reviewers, and other key stakeholders, in addition to statistical specialists. Join us in this unique forum that will catalyze progress in advancing innovation in drug development.


Need approval in order to attend?

Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.

Program Committee

  • Robert A. Beckman, MD
    Robert A. Beckman, MD Prof. of Oncology, Biostatistics, Bioinformatics, & Biomathematics-Adjunct Track
    Georgetown University Medical Center, United States
  • Fanni  Natanegara, PhD
    Fanni Natanegara, PhD Principal Research Scientist
    Eli Lilly and Company, United States
  • Zoran  Antonijevic, MS
    Zoran Antonijevic, MS Head of Biometrics
    MedSource, United States
  • Cristiana  Mayer, DrSc, PhD
    Cristiana Mayer, DrSc, PhD Director, Statistics and Decision Sciences
    Janssen Research & Development, LLC, United States
  • Dionne  Price, PhD
    Dionne Price, PhD Director, Division of Biometrics IV, Office of Biostatistics, OTS, CDER
    FDA, United States
  • Karen Lynn Price, PhD, MA
    Karen Lynn Price, PhD, MA Senior Research Advisor, Statistical Innovation Center
    Eli Lilly and Company, United States
  • Sesquile  Ramon, PhD, MS
    Sesquile Ramon, PhD, MS Director Science and Regulatory Affairs
    BIO, United States
  • Pritibha  Singh, MBA, MS
    Pritibha Singh, MBA, MS
    Novartis, Switzerland
  • Rui Sammi  Tang, PhD
    Rui Sammi Tang, PhD Senior Director, Head of Biostatistics Department
    Servier Pharmaceuticals, United States
  • Amy  Xia, PhD
    Amy Xia, PhD Vice President, Biostatistics, Design & Innovation
    Amgen Inc., United States
  • Maria  Apostolaros, JD, PharmD, MS, RPh
    Maria Apostolaros, JD, PharmD, MS, RPh
    PhRMA, United States
  • Yi  Liu, PhD
    Yi Liu, PhD Director Biostatistics
    Nektar Therapeutics, United States
Load More

Contact us

Registration Questions?

Send Email
1.888.257.6457


Digital Learning Catalog

DIA Learning: eLearning Soultions
Download